AryoGen
 | This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. (February 2014) |
 | This article needs additional citations for verification. (August 2012) |
AryoGen Biopharma (in Persian: آریوژن زیست دارو ) is a Iranian biopharmaceutical company specializing in manufacturing Therapeutic Monoclonal antibodies and some other recombinant proteins.
History
A group of scientific experts in a well experienced Biopharmaceutical company formed a totally new entity which started its production in 2010 with the name of AryoGen Biopharma. AryoGen was opened by Iranian president since its products is very crucial for community's health care system inside the country, in the region and around the world. AryoGen is the first company in the world, producing biosimilar form of Blood Coagulation Factor VII. For having this capability AryoGen has invested more than 50 million Euros in the production line. Also AryoGen has established production line for monoclonal antibodies which will stands among the list of 10 manufacturer of the world. These lines will start to industrial production early in the 2013.
Products
AryoGen's products include:
- Blood Coagulation factor VII with the name of AryoSeven which is a biosimilar form of Novoseven with multi billion dollars world market and is used for hemophilia patients and other conditions
- Altebrel with the generic name of Etanercept and original trade name of Enbrel which for some years was the no. one in the biopharmaceutical market and is used for treatment of autoimmune diseases
- Zytux with the generic name of Rituximab and original trade name of Rituxan which is an anticancer biomedicine,
- Hercease with the generic name of trastuzumab and original name of Herceptin which is a revolutionary drug in treatment of breast cancer
- Arvestin with the generic name of bevacizumab and original trade name of Avestin and is used for treatment of some sort of cancer.
AryoSeven is now approved by Iranian food and drug organisation and from Aug 2012 is in the market and other biomedicines are closing to the market.
References
- AryoGen press releases
- AryoGen homepage
Additional sources
- "IRAN, ISLAMIC REPUBLIC OF : Aryogen produces locally made medicines in Iran; helps Iran save up to $100 mln annually". Mena Report.
- World's 2nd factor VII factory opened in Iran. - Mehr News Agency (MNA) | HighBeam Research
- Iran launches domestic manufacture of anti-hemophilia drug - Trend.Az